- BioSyent (RX) has announced that the TSX Venture Exchange has accepted the company’s Notice of Intention to renew its NCIB
- BioSyent may purchase up to 740,000 of its common shares over a 12-month period
- The NCIB will commence on December 17, 2021 and end on December 16, 2022
- BioSyent is a pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and healthcare products
- BioSyent Inc. is down 3.33 per cent, trading at C$8.41 per share at 3:40 pm EST
BioSyent (RX) has announced that the TSX Venture Exchange has accepted the company’s Notice of Intention to renew its NCIB.
BioSyent may purchase up to 740,000 of its common shares over a 12-month period. The company has 12,579,858 common shares outstanding as of December 13, 2021.
The NCIB will commence on December 17, 2021, and end on December 16, 2022. Share purchases under the NCIB will be made through the TSXV at the market price. The company is able to purchase up to 251,597 shares during any 30-day period, representing 2 per cent of the total outstanding shares.
BioSyent has entered into an automatic share purchase plan with a broker, Raymond James Ltd. Shares will be purchased at the discretion of senior management of BioSyent.
BioSyent has repurchased and cancelled a total of 1,752,825 shares under NCIBs between December 10, 2018, and December 10, 2021.
BioSyent is a pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and healthcare products.
BioSyent Inc. is down 3.33 per cent, trading at C$8.41 per share at 3:40 pm EST.
